alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**Exhibit31.1**

**CERTIFICATION**

I, Robin Raina, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Ebix, Inc.;

2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, results of operations and cash flows of the registrantas of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused suchdisclosure controls and procedures to be designed under our supervision, toensure that material information relating to the registrant, including itsconsolidated subsidiaries, is made known to us by others within those entities,particularly during the period in which this report is being prepared;

(b) Evaluated the effectiveness of the registrant’s disclosure controlsand procedures and presented in this report our conclusions about theeffectiveness of the disclosure controls and procedures, as of the end of theperiod covered by this report based on such evaluation; and

(c) Disclosed in this report any change in the registrant’s internalcontrol over financial reporting that occurred during the registrant’s mostrecent fiscal quarter (the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and

5. The registrant’s other certifying officer and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):

(a) All significant deficiencies and material weaknesses in the designor operation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.
| Date:  October  31, 2007 | /s/ Robin Raina          |
|------------------------------------|--------------------------|
|                               | Robin Raina              |
|                               | Chief Executive  Officer |

 

----
Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Small Business Administration [Disaster Declaration #12055 and #12056]
 AGENCY: U.S. Small Business Administration.
 ACTION: Notice.
 SUMMARY: This is a Notice of the Presidential declaration of a major disaster for Public Assistance Only for the State of Nebraska (FEMA-1878-DR), dated 02/25/2010. *Incident:*
                         Severe Winter Storms and Snowstorm. *Incident Period:*
                         12/22/2009 through 01/08/2010.
 Effective Date: 02/25/2010. *Physical Loan Application Deadline Date:*
                         04/26/2010. *Economic Injury (EIDL) Loan Application Deadline Date:*
                         11/25/2010.
 ADDRESSES: Submit completed loan applications to: U.S. Small Business Administration, Processing and Disbursement Center, 14925 Kingsport Road, Fort Worth, TX 76155.
 FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster Assistance, U.S. Small Business Administration, 409 3rd Street, SW., Suite 6050, Washington, DC 20416.


SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of the President's major disaster declaration on 02/25/2010, Private Non-Profit organizations that provide essential services of governmental nature may file disaster loan applications at the address listed above or other locally announced locations. The following areas have been determined to be adversely affected by the disaster: *Primary Counties:*
                     Adams, Antelope, Brown, Burt, Butler, Cass, Cherry, Clay, Dakota, Dodge, Douglas, Gage, Garfield, Hamilton, Jefferson, Johnson, Keya Paha, Lancaster, Madison, Morrill, Nance, Nemaha, Otoe, Pawnee, Rock, Saline, Saunders, Seward, Stanton, Thayer, Thurston, Washington, Wheeler, York. The Interest Rates are: PercentFor Physical Damage:Non-Profit Organizations With Credit Available Elsewhere
3.625Non-Profit Organizations Without Credit Available Elsewhere
3.000For Economic Injury:Non-Profit Organizations Without Credit Available Elsewhere
3.000
 The number assigned to this disaster for physical damage is 12055B and for economic injury is 12056B. (Catalog of Federal Domestic Assistance Numbers 59002 and 59008) James E. Rivera, Associate Administrator for Disaster Assistance.


[FR Doc. 2010-4667 Filed 3-4-10; 8:45 am] BILLING CODE 8025-01-P
DISMISS; and Opinion Filed November 16, 2015.

S

In The

Court of Appeals

Fifth District of Texas at Dallas

No. 05-15-00639-CV

VILLAGE CRESTMONT HOUSTON USA, L.L.C. AND WEST CRESTMONT 

HOUSTON USA, L.L.C. D/B/A CRESTMONT VILLAGE APARTMENTS, Appellants

V.

JOSE J. GAITAN, INDIVIDUALLY AND D/B/A EC & J REMODELING & PAINTING, 

Appellee

On Appeal from the 191st Judicial District Court

Dallas County, Texas

Trial Court Cause No. DC-15-04688

MEMORANDUM OPINION NUNC PRO TUNC1

Before Justices Lang-Miers, Brown, and Schenck

Opinion by Justice Schenck

By order of September 23, 2015, we granted appellants’ counsel’s motion to withdraw. 

Because a corporation may only appear through an attorney, we directed appellants in that same 

order to file a notice designating new counsel within thirty days. See Kunstoplast of Am., Inc. v. 

Formosa Plastics Corp., 937 S.W.2d 455, 456 (Tex. 1996) (per curiam). We cautioned 

appellants that failure to timely obtain new counsel would result in dismissal of the appeal 

without further notice. To date, however, appellants have not designated new counsel or 

 1 This memorandum opinion nunc pro tunc corrects an error in the original opinion with respect to the style of the appeal.
–2–

otherwise communicated with the Court regarding the appeal. Accordingly, we dismiss the 

appeal.

150639F.P05

/David J. Schenck/

DAVID J. SCHENCK

JUSTICE
–3–

Court of Appeals

S

Fifth District of Texas at Dallas

JUDGMENT NUNC PRO TUNC

VILLAGE CRESTMONT HOUSTON 

USA, L.L.C. & WEST CRESTMONT 

HOUSTON USA, L.L.C. D/B/A 

CRESTMONT VILLAGE APARTMENTS, 

Appellants

No. 05-15-00639-CV V.

JOSE J. GAITAN, INDIVIDUALLY AND 

D/B/A EC & J REMODELING & 

PAINTING, Appellee

On Appeal from the 191st Judicial District 

Court, Dallas County, Texas

Trial Court Cause No. DC-15-04688.

Opinion delivered by Justice Schenck. 

Justices Lang-Miers and Brown 

participating.

In accordance with this Court’s opinion nunc pro tunc of this date, we DISMISS the 

appeal.

We ORDER appellee Jose J. Gaitan, Individually and d/b/a EC & J Remodeling & 

Painting recover his costs, if any, of this appeal from appellant Village Crestmont Houston USA, 

L.L.C. & West Crestmont Houston USA, L.L.C. d/b/a Crestmont Village Apartments.

Judgment entered this 16th day of November, 2015.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1810 Vitamin B12 test system. ( a ) *Identification.* A vitamin B12 test system is a device intended to measure vitamin B12 in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of anemias of gastrointestinal malabsorption.
( b ) *Classification.* Class II.
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.3645 Neuroleptic drugs radioreceptor assay test system. ( a ) *Identification.* A neuroleptic drugs radioceptor assay test system is a device intended to measure in serum or plasma the dopamine receptor blocking activity of neuroleptic drugs and their active metabolites. A neuroleptic drug has anti-psychotic action affecting principally psychomotor activity, is generally without hypnotic effects, and is a tranquilizer. Measurements obtained by this device are used to aid in determining whether a patient is taking the prescribed dosage level of such drugs.
( b ) *Classification.* Class II.
§ 582.3173 Butylated hydroxytoluene. ( a ) *Product.* Butylated hydroxytol- uene.
( b ) *Tolerance.* This substance is generally recognized as safe for use in food when the total content of antioxidants is not over 0.02 percent of fat or oil content, including essential (volatile) oil content of food provided the substance is used in accordance with good manufacturing or feeding practice.
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6570 Impression tube. ( a ) *Identification.* An impression tube is a device consisting of a hollow copper tube intended to take an impression of a single tooth. The hollow tube is filled with impression material. One end of the tube is sealed with a softened material, such as wax, the remaining end is slipped over the tooth to make the impression.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 30097, Aug. 12, 1987, as amended at 54 FR 13831, Apr. 5, 1989; 66 FR 38800, July 25, 2001]
Exhibit 35.1




Servicer Compliance Statement of Nissan Motor Acceptance Corporation









NISSAN MOTOR ACCEPTANCE CORPORATION




OFFICER'S CERTIFICATE


The undersigned, Mark Kaczynski, President and Chief Executive Officer of NISSAN MOTOR ACCEPTANCE CORPORATION, a California corporation (the “Company”), does hereby certify, in his capacity as such corporate officer, as follows:
  (1)           The undersigned has caused a review of the activities of the Company, in its capacity as Servicer, during the period July 22, 2015 through March 31, 2016 (the “Reporting Period”), and of its performance pursuant to the Sale and Servicing Agreement, dated as of July 22, 2015 (the “Agreement”), by and among the Company, individually and as servicer, Nissan Auto Receivables Corporation II, as seller, and Nissan Auto Receivables 2015-B Owner Trust, to be conducted under his supervision; and
  (2)           To the best of the undersigned’s knowledge, based upon such review, the Company has fulfilled all of its obligations under the Agreement in all material respects throughout the Reporting Period.
  This Officer’s Certificate is being furnished pursuant to Item 1123 of the Securities and Exchange Commission’s Regulation AB for publicly-issued asset-backed securities.  Capitalized terms used but not defined herein shall have the meanings assigned to such terms in the Agreement.


IN WITNESS WHEREOF, I have set my hand effective as of the 15th day of June, 2016.




/s/ Mark Kaczynski_________________


Mark Kaczynski


President and Chief Executive Officer
§ 820.40 Document controls. Each manufacturer shall establish and maintain procedures to control all documents that are required by this part. The procedures shall provide for the following: ( a ) *Document approval and distribution.* Each manufacturer shall designate an individual(s) to review for adequacy and approve prior to issuance all documents established to meet the requirements of this part. The approval, including the date and signature of the individual(s) approving the document, shall be documented. Documents established to meet the requirements of this part shall be available at all locations for which they are designated, used, or otherwise necessary, and all obsolete documents shall be promptly removed from all points of use or otherwise prevented from unintended use.
( b ) *Document changes.* Changes to documents shall be reviewed and approved by an individual(s) in the same function or organization that performed the original review and approval, unless specifically designated otherwise. Approved changes shall be communicated to the appropriate personnel in a timely manner. Each manufacturer shall maintain records of changes to documents. Change records shall include a description of the change, identification of the affected documents, the signature of the approving individual(s), the approval date, and when the change becomes effective.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2810 Paper chart recorder. ( a ) *Identification.* A paper chart recorder is a device used to print on paper, and create a permanent record of the signal from, for example, a physiological amplifier, signal conditioner, or computer.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
[45 FR 7907, Feb. 5, 1980, as amended at 61 FR 1121, Jan. 16, 1996; 66 FR 38796, July 25, 2001]
{In Archive} Fw: Monthly call

Carl Young to: Dayana Medina 03/29/2011 12:21 PM

From: Carl Young/R6/USEPA/US

To: Dayana Medina/R6/USEPA/US@EPA

History: This message has been forwarded.

Archive: This message is being viewed in an archive.

Hi Dayana,

Below are the attachments.

Carl

Carl Young

EPA Region 6 Air Planning Section

214-665-6645

----- Forwarded by Carl Young/R6/USEPA/US on 03/29/2011 12:21 PM -----

From: "Walker Williamson" <Walker.Williamson@tceq.texas.gov>

To: Carl Young/R6/USEPA/US@EPA

Cc: "Donna Huff" <Donna.Huff@tceq.texas.gov>, "Guy Hoffman" <Guy.Hoffman@tceq.texas.gov>

Date: 03/25/2011 02:58 PM

Subject: Re: Monthly call

Hey, Carl:

Sorry, but we have one more item for the agenda. I got this from Nina Castillo on our Mobile 

Source Programs Team:

On Tuesday's conference call, we would like to discuss the TCEQ proposed idling rulemaking. We need 

some clarification with regards to the rulemaking proposal comments submitted by the EPA on March 

10, 2011. The EPA expressed concern that the proposal to retain the exemption for a motor vehicle 

when idling for heating or air conditioning while a driver is using the vehicle's sleeper berth for a 

government-mandated rest period will allow an emission increase over the approved State 

Implementation Plan (SIP). In the Dallas-Fort Worth (DFW) Attainment Demonstration SIP, the idling 

restrictions emission reductions are part of the Voluntary Mobile Source Emission Reduction Programs 

(VMEP) commitments. The attached North Central Texas Council of Governments (NCTCOG) Voluntary 

Mobile Source Emission Reduction Program and Other Local Program Achievements document indicates 

the DFW achieved an excess of NOX

 reduction through the VMEP commitments, indicating that VMEP 

commitments could be achieved without the vehicle idling reductions.

>>> <Young.Carl@epamail.epa.gov> 3/25/2011 8:46 AM >>>

Hi Walker,

I'll add these topics. Also, I'll "185 Fees Update".

Talk with you all Tuesday at 2.
**UN PUBLISHED** 
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

**No. 1**  **0 -**  **6 9**  **50**

LONNIE GETER , P etitioner

– Appell ant ,
v. MICHAEL MCCALL, Warden of Perry Correctional Institution , Responde nt

– Appell ee .

Appeal from the United States Dis trict Court for the District of South Carolina , at Anderson
. Patrick Michael Duffy , Senior District Judge. ( 8 :0 9

- cv - 0 1589

- PMD )

Submitted : January 28, 2011 Decided: February 1 5 , 2011

Before MOTZ, DUNCAN, and WYNN, Circuit Judge s .
Dismiss ed by u n published per curiam opinion
.
Lonnie Geter , Appellant Pro Se. Donald John Zelenka, Deputy Assistant Attorney General, Samuel Creighton Waters , Assistant Attorney General , Columbia, South Carolina, for Appellee.
Unpublished opinions are not binding p recedent in this circuit.2 PER CURIAM: Lonnie Geter seeks to appeal the district court’s order accepting the recommendation of the magistrate judge and denying relief on his 28 U.S.C. § 2254 (2006) petition. The order is not appealable unless a circuit ju stice or judge issues a certificate of appealability. 28 U.S.C. § 2253(c)(1) (2006)
. A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2) (2006)
. When the district court denies relief on the merits, a prisoner satisfies this standard by demonstrating that reasonable jurists would find that the district court’s assessment of the constitutional claims is debatable or wrong. Slack v. McDaniel , 529 U.S. 473, 484 (2000); see Miller

- El v. Cockrell , 537 U.S. 322, 336

- 38 (2003). When the district court denies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is debatable, and that the petition states a debatable claim of the denial of a constitutional right. Slack , 529 U.S. at 484

- 85. We have independently review ed the record and conclude that Geter has not made the requisite showing. Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispe nse with oral argument because the facts and legal contentions are adequately presented in the materials3 before the court and argument would not aid the decisional
process. DISMISSED
Exhibit 99.2

 CERTIFICATION PURSUANT TO 18 U.S. SECTION 1350, AS ADOPTED PURSUANT TO SECTION
                      906 OF THE SARBANES-OXLEY ACT OF 2002


     Pursuant to 18 U.S.C. (S)1350, as adopted pursuant to (S)906 of the
Sarbanes-Oxley Act of 2002, each of the undersigned officers of GlycoGenesys,
Inc. (the "Company"), hereby certifies, to his knowledge, that:

     (1) the Company's annual report on Form 10-K/A for the year ended December
31, 2001 (the "Report") fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company as of and for the periods presented in the Report.


Dated: December 18, 2002


By: /s/ John W. Burns                       By: /s/ Bradley J. Carver
    -------------------------                   ---------------------------
Name: John W. Burns                         Name: Bradley J. Carver
Title: SVP, CFO & Secretary                 Title: CEO & President
§ 640.91 Processing. ( a ) *Date of manufacture.* The date of manufacture shall be the date of final sterile filtration of a uniform pool of bulk solution.
( b ) *Processing method.* The processing method shall not affect the integrity of the product, and shall have been shown to yield consistently a product which: ( 1 ) After the heating prescribed in paragraph (e) of this section does not show an increase in the components with electrophoretic mobility similar to that of alpha globulin that amounts to more than 5 percent of the total protein.
( 2 ) Contains less than 5 percent protein with a sedimentation coefficient greater than 7.0 S.
( 3 ) Is safe for intravenous injection.
( c ) *Microbial contamination.* All processing steps shall be conducted in a manner to minimize the risk of contamination from microorganisms, pyrogens, or other impurities. Preservatives to inhibit growth of microorganisms shall not be used during processing.
( d ) *Storage of bulk fraction.* Bulk concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of −5 °C or colder. Any other bulk form of the product (exclusive of the sterile bulk solution) to be held more than 1 week prior to further processing, shall be stored in clearly identified closed vessels at a temperature of 5 °C or colder. Any bulk fraction to be held one week or less prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 °C or colder.
( e ) *Heat treatment.* Heating of the final containers of Plasma Protein Fraction (Human) shall begin within 24 hours after completion of filling. Heat treatment shall be conducted so that the solution is heated continuously for not less than 10 or more than 11 hours at an attained temperature of 60±0.5 °C.
( f ) *Stabilizer.* Either 0.08±0.016 millimole sodium caprylate, or 0.08±0.016 millimole sodium acetyltryptophanate and 0.08±0.016 millimole sodium caprylate per gram of protein shall be present as a stabilizer(s). Calculations of the stabilizer concentration may employ the labeled value 5 percent for the protein concentration of the product.
( g ) *Incubation.* All final containers of Plasma Protein Fraction (Human) shall be incubated at 20 to 35 °C for at least 14 days following the heat treatment prescribed in paragraph (e) of this section. At the end of this incubation period, each final container shall be examined and all containers showing any indication of turbidity or microbial contamination shall not be issued. The contents of turbid final containers shall be examined microscopically and tested for sterility. If growth occurs, the types of organisms shall be identified as to genus and the material from such containers shall not be used for further manufacturing.
[42 FR 27583, May 31, 1977, as amended at 64 FR 26286, May 14, 1999]
§ 556.1 Scope. ( a ) The Federal Food, Drug, and Cosmetic Act requires an applicant seeking approval or conditional approval of a new animal drug to submit a proposed tolerance as part of its new animal drug application when such a tolerance is needed to assure that the proposed use of the new animal drug will be safe (see sections 512(b)(1)(H) and 571(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act). FDA assigns tolerances for animal drugs used in food-producing animals as part of the application approval process. Tolerances for approved and conditionally approved new animal drugs are codified in subpart B of this part.
( b ) Compounds that have been found to be carcinogenic are regulated under subpart E of part 500 of this chapter.